

# Progenics Cord Blood Cryobank Annual Quality Report



QA.006-3-EXT V1.2 Effective Date: 2021-06-11

# Company Profile

---

Progenics Cord Blood Cryobank is a leader in delivering consistent, high quality cord blood processing results, with over 16 years of experience in the cord blood banking industry. Progenics is AABB and FACT Accredited and is registered with both Health Canada and the Food and Drug Administration (FDA) in the United States. The company's mission is to provide the highest quality processing and long-term safe, secure storage of cord blood stem cells, to ensure their availability when needed.

Progenics Cord Blood Cryobank's *modified double stem cell extraction processing technique*, developed by the company's Research and Development Team, ensures that we can guarantee every processed cord blood sample will yield the highest possible number of Total Nucleated Cells (TNC).

## Contact Us:

Toll Free: 1-866-921-1666

Phone: 416-221-1666

Email: [info@progenics.ca](mailto:info@progenics.ca)

Address: 701 Sheppard Avenue East  
Suite 310,  
Toronto, ON- M2K 2Z3  
Canada

Website: [www.progenics.ca](http://www.progenics.ca)

# Report Summary

---

This quality report summarizes the processing results from all the cord blood samples processed by Progenics Cord Blood Cryobank from January 2020 to December 2020. The quality indicators referenced in this report present 5 key variables: the yield (%) of Total Nucleated Cells (TNC), Total Viable Nucleated Cells (TVNC), CD34+ Viability, Total Nucleated Cell Count, and Viable CD34+ Cell Count.

This report also compares the average monthly and annual percentage yields of TNC including stem cells, the average percentage of total viable nucleated cells, and the average percentage of viable CD34+ cells.

Progenics uses a *modified double stem cell extraction processing technique* which ensures that a higher number of viable nucleated cells are banked for potential medical need. Based on this technique, the average recovery rate for TNCs banked has been 97.46%, which is significantly greater than the industry and shows our dedication to maintaining the highest quality standards for each client.

# 2020 Monthly Report

Month	Total Nucleated Cells (TNC) Yield (%)	Total Viable Nucleated Cells (TVNC) (%)	CD34+ Viability (%)	Total Nucleated Cell Count (x10 <sup>6</sup> /unit)	Viable CD34+ Cell Count (x10 <sup>6</sup> /unit)
January	97.09	93.15	99.41	856.03	2.80
February	95.80	92.95	99.12	754.44	2.35
March	95.27	94.12	99.18	882.96	3.05
April	95.26	94.93	99.37	811.83	2.69
May	95.52	92.87	98.95	788.16	2.53
June	95.02	95.70	99.51	736.27	2.01
July	93.73	94.26	99.57	834.22	2.79
August	93.20	93.58	98.77	695.90	2.46
September	93.63	95.50	99.24	729.13	2.99
October	94.00	94.72	99.22	904.14	2.92
November	96.68	93.37	99.10	928.34	3.75
December	95.78	94.59	99.46	978.04	4.08
<b>Annual average</b>	<b>95.08</b>	<b>94.15</b>	<b>99.24</b>	<b>824.96</b>	<b>2.81</b>


## Notes:

**TNC** TNC includes all nucleated cells such as stem cells and nucleated red blood cells.

**TVNC** Total Viable Nucleated Cells

**CD34+ Cells** Hematopoietic Progenitor Cells

**Viability** Cell viability is the percentage of viable cells in a processed cord blood sample. The viability of cells is evaluated by either measurement of cell membrane integrity or by measuring certain functions of the cells from a total cell sample.



---

## Conclusion: Comparing Annual Averages

Based on the above data, we can confidently report that for 2020:

- ✓ The average annual percentage yield of **Total Nucleated Cells (TNC)** was: **95.08%**
- ✓ The average annual percentage of **Total Viable Nucleated Cells** was:
- ✓ The average annual percentage of **viable CD34<sup>+</sup>** cells was:
- ✓ The average annual Total Nucleated Cell count (x10<sup>6</sup>/unit) was:
- ✓ The average annual Viable CD34+ Cell count (x10<sup>6</sup>/unit) was:

The above results have been made possible due to our *modified double stem cell extraction processing technique* which surpasses our internal quality standards by over 10%.

Progenics quality policy assures that processed cord blood units (CBU) will contain the highest possible yield of total nucleated cells (TNC). Once a client's CBU has been processed, and all processing parameters meet our cord blood bank acceptance criteria, the client will receive a *Certificate of Cryopreservation* which contains quality indicators of cord blood processing results.

After reviewing the data within this report, we can confidently claim that we offer our clients the highest consistent cord blood processing results.